ReviewFrontiers in immunology2026
Transcending risk factors: the implications of redefining diabetes as an immunometabolic disease for infectious disease studies.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Post-acute metabolic changes and risk of new-onset diabetes following COVID-19: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review methodically argues for a theoretical paradigm shift. The text redefines diabetes as an "immunometabolic disorder" and explores its profound implications. Conventional wisdom has long regarded diabetes as a risk factor for infectious disease comorbidity. Nevertheless, this perspective lacks the depth necessary to elucidate the underlying mechanisms involved. Preliminary clinical research suggests that individuals with diabetes have a 2- to 4-fold higher probability of requiring hospitalization due to infections in comparison with individuals who do not have diabetes. During the pandemic, there was a notable surge in severe illness and mortality rates. These findings suggest limitations in the traditional explanatory framework centered solely on glycemic control. The new paradigm focuses on the co-dysregulation of immunity and metabolism, elucidating how factors such as hyperglycemia and lipotoxicity interact to ultimately drive chronic inflammation and immune dysfunction. This framework elucidates the underlying mechanisms that render individuals with diabetes more vulnerable to various pathogens, expedite disease progression following infection, and manifest diminished therapeutic and vaccine responses. The review further posits that this understanding should inform clinical practice. Rather than prioritizing solely glycemic control, a comprehensive approach to management should encompass metabolic regulation, immune assessment, and infection prevention. Public health policies must explicitly categorize diabetic patients as a priority group for protection. Despite the challenges associated with precise subtyping and the development of targeted interventions, the potential benefits of interdisciplinary efforts and precision medicine strategies are noteworthy. A critical imperative for diabetes management is a transition from a blood glucose control-centric approach to a comprehensive intervention strategy aimed at restoring immune-metabolic homeostasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.